3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Squamous Cell Carcinoma of Head and Neck
5
Skin Neoplasms
5
Neoplasm Metastasis
5
Melanoma
5
Lung Neoplasms
5
Carcinoma
5
Recurrence
4
Neoplasms
4
Mouth Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Adenocarcinoma
3
Ovarian Neoplasms
2
Mycosis Fungoides
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, B-Cell
2
Laryngeal Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Squamous Cell
2
Vaccinia
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Solid Tumors
1
Interventions
pembrolizumab
44
Carboplatin
35
Paclitaxel
27
Specimen Handling
18
Cyclophosphamide
16
Capecitabine
16
Magnetic Resonance Spectroscopy
14
sacituzumab govitecan
13
Gemcitabine
13
Taxes
12
Biopsy
12
130-nm albumin-bound paclitaxel
11
Albumin-Bound Paclitaxel
9
Doxorubicin
8
olaparib
7
Nivolumab
7
fludarabine
6
Cisplatin
6
eribulin
5
atezolizumab
5
Radiotherapy
5
Docetaxel
5
durvalumab
4
Fulvestrant
4
Epirubicin
4
Bevacizumab
4
veliparib
3
famitinib
3
abemaciclib
3
Vinorelbine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
cemiplimab
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled